Samsung Biologics recently gave up developing SAIT101, a biosimilar of follicular lymphoma treatment Rituxan (ingredient: rituximab), which it had promoted as its first product since entering the bio business.According to the Samsung Biologics’ quarterly report released on Monday, the company and As
Helixmith said Thursday the first enrolled patient has received its new gene therapy, Engensis (VM202), in phase 3-2 study of diabetic peripheral neuropathy (DPN).The company plans to continue administering the drug to other participants, as it is screening many additional patients at five clinical
Korean pharmaceuticals are going all out to develop Covid-19 vaccines and treatments with extensive government support but will have to go a long way before reaching their destinations, industry watchers said.The gloomy outlook came in the wake of news reports on multinationals’ hitting the jackpot
The Korea Health Industry Development Institute (KHIDI) and Roche Korea said they would work together to build a precision medical ecosystem in Korea.The accord is the first case of an investment agreement between a Korean government agency and a global pharmaceutical company in the field of precisi
SK Plasma said it has become the first Korean company to supply its blood product, Albumin 20 percent inj., to the North Atlantic Treaty Organization (NATO).The drugmaker competed with global pharmaceutical companies to snatch NATO’s Afghanistan National Army Trust Fund project last June, sponsored
Janssen Korea said that it has officially launched Spravato, a treatment-resistant depression drug, in Korea.It is the first therapy for treatment-resistant depression and is also the first nasal spray drug in major depressive disorders, which uses a new mechanism for the first time in 30 years."The
GC Cell’s Immuncell-LC, customized immunotherapy, recorded the largest quarterly sales in the third quarter this year, five years after its market release, the company said.However, the company will have to address a delayed integration of the new and old manufacturing facilities to improve operatin
Samsung Biologics said Tuesday it has concluded a long-term contract with Eli Lilly to manufacture the antibody-drug neutralizing Covid-19.The Korean company signed a contract manufacturing organization (CMO) agreement with the multinational pharma in May to supply the drug treating the novel corona
Viatris, a global pharmaceutical company formed by the merger of the Upjohn division of Pfizer and Mylan, said it would begin a restructuring program to save $1 billion immediately after the company's launch.Observers said Viatris’s downsizing plan might affect workers in the Korean offshoot.On Mond
MedPacto has confirmed the clinical efficacy of its Vactosertib response gene signature (VRGS), a biomarker under development, which can find colon cancer patients who will respond to combined therapy. The company’s VRGS can tell who will show a therapeutic response when administered Vactosertib com
The Russian Direct Investment Fund (RDIF) said that GL Rapha, a Korean biotech firm, will manufacture 150 million doses of Sputnik V, a Russian-developed Covid-19 vaccine, annually.Under the accord, GL Rapha, including its subsidiary Hankook Korus Pharma, will begin manufacturing the vaccines next m
Korea will become an integral part of fighting off future pandemics with the nation's accumulated experience from fighting Covid-19, according to Trevor Mundel, president of Global Health at the Bill & Melinda Gates Foundation and chair of the RIGHT (Research Investment for Global Health Technology)
Lundbeck Korea and its labor union reached a tentative deal on a new labor contract Wednesday night and averted a collective action.Lundbeck Korea and the union made a provisional agreement on all 141 issues, according to the union. The tentative deal includes guaranteeing the union's basic activiti
Daewoong Pharmaceutical said Wednesday that it has confirmed the efficacy of its combination drug, “Olostar,” which treats hypertension and dyslipidemia, and published its research in the "American Journal of Therapeutics." The company conducted clinical trials on 112 patients over 18 suffering from
Pharmaceutical industry officials have become increasingly worried about a confirmed Covid-19 case in a drug sales representative at a local company.According to sources on Wednesday, one employee of Handok was diagnosed with Covid-19 infection, and two more Handok workers got the viral infection.Th
The share prices of Covid-19-related biopharmaceutical companies widened losses on Wednesday morning, upon news that Pfizer and BioNTech’s vaccine has shown an efficacy rate of over 90 percent in a phase 3 trial.As of 12:30 p.m., Genexine, which had been conducting trials for GX-19, registered the l
Korean drugmakers made technology export of 9.1 trillion won ($8.18 billion) in the first 10 months of this year, hitting a record high amid the Covid-19 pandemic, an industry group said recently. According to a report by the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA), dom
Hanmi Pharmaceutical said that the Ministry of Food and Drug Safety has approved its Amosartan XQ, the world's first four combination therapy.The drug, which treats hypertension and hyperlipidemia, combines two hypertension treatments -- amlodipine and losartan – with two dyslipidemia treatments of
The outpatient prescription amount of choline alfoscerate drugs has continued to grow as the result of an increase in long-term prescription despite the controversy over its effectiveness, according to market sources.According to UBIST, a drug market surveyor, the prescription for choline alfoscerat
Deargen Inc., an AI-based drug developer, said that it signed a contract with SK Chemical last week to conduct joint researches on “drug repositioning” and “de novo drug design.” Under the agreement, Deargen will carry out drug repositioning – inducing effective substance from existing medicines or